151 related articles for article (PubMed ID: 3512426)
1. Rapid killing of actinomycin D-treated tumour cells by mononuclear phagocytes: reactivity in mouse strains with defective classical tumour cytotoxicity.
Collota F; Bersani L; Polentarutti N; Mantovani A
Immunology; 1986 Feb; 57(2):249-53. PubMed ID: 3512426
[TBL] [Abstract][Full Text] [Related]
2. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
3. Rapid killing of actinomycin D-treated tumor cells by mononuclear phagocytes: characterization of effector cells in mice.
Colotta F; Polentarutti N; Bersani L; Poli G; Mantovani A
J Leukoc Biol; 1986 Feb; 39(2):205-21. PubMed ID: 3455716
[TBL] [Abstract][Full Text] [Related]
4. Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella.
Schafer R; Nacy CA; Eisenstein TK
J Immunol; 1988 Mar; 140(5):1638-44. PubMed ID: 3279120
[TBL] [Abstract][Full Text] [Related]
5. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
6. Characterization of genetic defects in macrophage tumoricidal capacity: identification of murine strains with abnormalities in secretion of cytolytic factors and ability to bind neoplastic targets.
Adams DO; Marino PA; Meltzer MS
J Immunol; 1981 May; 126(5):1843-7. PubMed ID: 6783698
[TBL] [Abstract][Full Text] [Related]
7. Involvement of tumour necrosis factor in monocyte-mediated rapid killing of actinomycin D-pretreated WEHI 164 sarcoma cells.
Bersani L; Colotta F; Mantovani A
Immunology; 1986 Oct; 59(2):323-5. PubMed ID: 3770807
[TBL] [Abstract][Full Text] [Related]
8. Defective tumoricidal capacity of macrophages from P/J mice: tumoricidal defect involves abnormalities in lymphokine-derived activation stimuli and in mononuclear phagocyte responsiveness.
Boraschi D; Meltzer MS
J Immunol; 1980 Aug; 125(2):777-82. PubMed ID: 6993563
[No Abstract] [Full Text] [Related]
9. Antileishmanial activities of macrophages from C3H/HeN and C3H/HeJ mice treated with Mycobacterium bovis strain BCG.
Pappas MG; Nacy CA
Cell Immunol; 1983 Sep; 80(2):217-22. PubMed ID: 6349826
[TBL] [Abstract][Full Text] [Related]
10. Macrophages as cytotoxic effector cells.
Lohmann-Matthes ML; Lang H; Sun D
Immunobiology; 1982 Apr; 161(3-4):401-7. PubMed ID: 7047379
[TBL] [Abstract][Full Text] [Related]
11. Defective tumoricidal capacity of macrophages from P/J mice: characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli.
Boraschi D; Meltzer MS
J Immunol; 1980 Aug; 125(2):771-6. PubMed ID: 6993562
[TBL] [Abstract][Full Text] [Related]
12. Defective tumoricidal capacity of macrophages from C3H/HeJ mice.
Ruco LP; Meltzer MS
J Immunol; 1978 Jan; 120(1):329-34. PubMed ID: 627723
[TBL] [Abstract][Full Text] [Related]
13. Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice.
Boraschi D; Meltzer MS
J Immunol; 1979 Apr; 122(4):1592-97. PubMed ID: 376721
[No Abstract] [Full Text] [Related]
14. Cytotoxicity on tumour cells of human mononuclear phagocytes: defective tumoricidal capacity of alveolar macrophages.
Bordignon C; Avallone R; Peri G; Polentarutti N; Mangioni C; Mantovani A
Clin Exp Immunol; 1980 Aug; 41(2):336-42. PubMed ID: 6160006
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages.
Biondi A; Peri G; Colombo N; Bolis G; Mantovani A
Clin Exp Immunol; 1982 Sep; 49(3):701-8. PubMed ID: 7172502
[TBL] [Abstract][Full Text] [Related]
16. Rapid killing of actinomycin D-treated tumor cells by human monocytes. II. Cytotoxicity is independent of secretion of reactive oxygen intermediates and is suppressed by protease inhibitors.
Colotta F; Bersani L; Lazzarin A; Poli G; Mantovani A
J Immunol; 1985 May; 134(5):3524-31. PubMed ID: 4038989
[TBL] [Abstract][Full Text] [Related]
17. Macrophages as effector cells of protective immunity in murine schistosomiasis. V. Variation in macrophage schistosomulacidal and tumoricidal activities among mouse strains and correlation with resistance to reinfection.
James SL; Skamene E; Meltzer MS
J Immunol; 1983 Aug; 131(2):948-53. PubMed ID: 6863937
[TBL] [Abstract][Full Text] [Related]
18. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
Taramelli D; Varesio L
J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
[TBL] [Abstract][Full Text] [Related]
19. Defective tumoricidal capacity of macrophages from A/J mice. I. Characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli.
Boraschi D; Meltzer MS
J Immunol; 1979 Apr; 122(4):1587-91. PubMed ID: 376720
[TBL] [Abstract][Full Text] [Related]
20. The ADCC capacity of macrophages from C3H/HeJ and A/J mice can be augmented by BCG.
Koren HS; Meltzer MS; Adams DO
J Immunol; 1981 Mar; 126(3):1013-5. PubMed ID: 7007498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
